Neurotoxicity

# Proactive Risk Assessment for Safer Drug Development

Predicting Neurotoxicity with Precision

Neurotoxicity is a critical aspect of drug development, ensuring that candidate compounds do not induce unintended effects on the central nervous system. Adverse CNS outcomes, such as seizures, cognitive impairment, or neurotoxicity, can derail clinical trials and result in significant delays. At VitroVo, we combine advanced MEA platforms, AI-driven analytics, and tailored models to deliver predictive, actionable insights that help de-risk your pipeline.

Why Neurotoxicity Profiling Matters

Unanticipated CNS effects can lead to regulatory hurdles and clinical failure. Early and accurate assessment of Neurotoxicity allows researchers to:

  • Identify seizure liability and other functional risks.
  • Reduce the likelihood of adverse events in clinical trials.
  • Improve the overall success rate of drug development.
  • Minimize reliance on animal testing with in-vitro assays that replicate human CNS function.

VitroVo’s Expertise in Neurotoxicity Assessment

State-of-the-Art Electrophysiology and Analytics:

MEA Technology:

  • Measure neuronal excitability and network activity to predict CNS effects.
  • Perform high-resolution analyses with HD-MEA platforms, capable of single-cell functional recording.

AI-Powered Safety Insights:

  • Use machine learning algorithms to identify patterns and predict CNS-related risks.
  • Multivariate analysis (e.g., PCA, UMAP) ensures comprehensive data interpretation.

Robust Safety Testing Across Key Parameters:

Seizure Liability:

  • Determine pro-seizure potential and identify dose thresholds aligned with in vivo outcomes.
  • Utilize well-established seizurogenic markers from electrophysiological data.

Neurotoxicity:

  • Assess compound-induced damage to neurons and glial cells using validated assays.
  • Measure synaptic activity and network stability for signs of functional impairment.

VitroVo’s Tailored Capabilities for Neurotoxicity Profiling

Advanced CNS Models:

  • Human iPSC-Derived Neurons: Glutamatergic, GABAergic, and dopaminergic neurons offer comprehensive coverage of CNS functions.
  • Brain Organoids and Slices:: Model complex 3D neural networks for realistic assessments of compound effects.
  • Co-Culture Systems:: Investigate neuron-glia interactions to predict long-term CNS impacts.

Enhanced Assays for Comprehensive Profiling:

  • Calcium Imaging: Monitor real-time intracellular calcium dynamics as a marker for neuronal excitability.
  • Biomarker Analysis (ELISA): Detect CNS-specific biomarkers, including those linked to inflammation and stress responses.
  • Gene Expression Profiling (RNA-seq, RT-qPCR): Study transcriptional changes to assess neurotoxicity and validate mechanistic pathways.

Why VitroVo is the Trusted Partner for Neurotoxicity

Benefits of Choosing VitroVo:

  • Validated Predictive Models: Reduce uncertainty in drug safety with highly reliable in-vitro assays.
  • Comprehensive Insights: Integrate data from MEA, imaging, and molecular profiling to ensure thorough CNS evaluations.
  • Cost-Effective Solutions: Save time and resources by predicting CNS risks early in the drug discovery process.

Partner with VitroVo for Neurotoxicity Excellence

At VitroVo, we provide cutting-edge solutions for Neurotoxicity profiling, leveraging decades of expertise and innovative technologies. Whether you are screening for seizure liability or evaluating neurotoxic effects, our team can support your drug development needs with precision and efficiency.

Contact Us:

Discover how VitroVo can help you ensure the Neurotoxicity of your candidate compounds. Reach out to our team today!

Assays

See assay examples below to find out how VitroVo can advance your neurotoxicity research

Predicting Seizurogenic Dose Levels with MEA and PCA for In Vitro to In Vivo Extrapolation
Predicting Seizurogenic Dose Levels with MEA and PCA for In Vitro to In Vivo Extrapolation

This assay presents a predictive method for assessing seizure liability using microelectrode array (MEA) assays combined with principal component analysis (PCA). By evaluating in vitro neural activity in co-cultured human iPSC-derived neurons with astrocytes, researchers established correlations between MEA data and in vivo cerebrospinal fluid (CSF) concentrations of convulsants. The findings support the potential of MEA assays to replace animal experiments by providing accurate in vitro to in vivo extrapolation (IVIVE) for seizurogenic risk assessment.
In Vitro EEG for Seizure Liability & Antiepileptic Drug Screening
In Vitro EEG for Seizure Liability & Antiepileptic Drug Screening

Explore how in vitro EEG analysis of brain organoids coupled with microelectrode arrays (MEA) provides a reliable method for assessing seizure liability and screening antiepileptic drugs. Discover insights into drug safety and neuropharmacology.
AI-Powered Raster Plot Analysis for Predicting Drug-Induced Seizure Liability
AI-Powered Raster Plot Analysis for Predicting Drug-Induced Seizure Liability

Discover how deep learning and microelectrode array (MEA) analysis using iPSC-derived neurons enable high-accuracy seizure liability prediction and drug identification. This AI-driven approach achieves up to 99.9% accuracy in classifying seizure-causing compounds, paving the way for advanced in vitro toxicity assessment.
High-Density CMOS-MEA | Single-Cell Resolution for Drug Response Analysis
High-Density CMOS-MEA | Single-Cell Resolution for Drug Response Analysis

Discover how high-density CMOS-MEA with 236,880 electrodes enables unprecedented single-cell resolution for drug response evaluation in hiPSC-derived cortical neurons. Gain deeper insights into seizure liability and neural network function.